Stress Odorant Sensory Response Dysfunction in Drosophila Fragile X Syndrome Mutants

Sensory processing dysfunction (SPD) is present in most patients with intellectual disability (ID) and autism spectrum disorder (ASD). Silencing expression of the Fragile X mental retardation 1 ( ) gene leads to Fragile X syndrome (FXS), the most common single gene cause of ID and ASD. have a highly...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in molecular neuroscience Vol. 11; p. 242
Main Authors Androschuk, Alaura, He, Richard X, Weber, Savannah, Rosenfelt, Cory, Bolduc, Francois V
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 08.08.2018
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Sensory processing dysfunction (SPD) is present in most patients with intellectual disability (ID) and autism spectrum disorder (ASD). Silencing expression of the Fragile X mental retardation 1 ( ) gene leads to Fragile X syndrome (FXS), the most common single gene cause of ID and ASD. have a highly conserved FMR1 ortholog, . mutants display cognitive and social defects reminiscent of symptoms seen in individuals with FXS. We utilized a robust behavioral assay for sensory processing of the stress odorant (dSO) to gain a better understanding of the molecular basis of SPD in FXS. Here, we show that mutant flies present significant defects in dSO response. We found that expression in mushroom bodies is required for dSO processing. We also show that cyclic adenosine monophosphate (cAMP) signaling via PKA is activated after exposure to dSO and that several drugs regulating both cAMP and cyclic guanosine monophosphate (cGMP) levels significantly improved defects in dSO processing in mutant flies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Regina Dahlhaus, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Reviewed by: Efthimios M. C. Skoulakis, Alexander Fleming Biomedical Sciences Research Center, Greece; Barbara Bardoni, UMR7275 Institut de Pharmacologie Moléculaire et Cellulaire (IPMC), France
ISSN:1662-5099
1662-5099
DOI:10.3389/fnmol.2018.00242